echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: The long-term efficacy of imiizumab prevention in patients with hemophilia A

    Blood: The long-term efficacy of imiizumab prevention in patients with hemophilia A

    • Last Update: 2021-05-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Patients with hemophilia A (PwHA) lack factor VIII (FVIII), leading to spontaneous and traumatic bleeding, most commonly joint, muscle and soft tissue bleeding; intracranial bleeding can be life-threatening.


    Subcutaneous injection of bispecific humanized monoclonal antibody emicizumab for prevention can promote effective hemostasis in patients with hemophilia A.


    prevention

    This article reports a pooled analysis of 4 phase III studies (HAVEN 1, HAVEN 2, HAVEN 3, and HAVEN 4) to clarify the long-term efficacy, safety, and pharmacokinetic characteristics of imiizumab .


    Clarify the long-term efficacy, safety and pharmacokinetic characteristics of imiizumab

    The analysis covered a total of 401 pediatric and adult PwHA patients with or without factor VIII (FVIII) inhibitors.


    Annual bleeding rate

    Annual bleeding rate

    As of May 15, 2020, the overall intermediate validity period is 120.


    The overall intermediate duration was 120.


    Adverse events

    Adverse events

    Imiizumab was well tolerated, and no subject was discontinued due to adverse events more than 5 times previously reported .


    Imiizumab was well tolerated, and no subject interrupted the blood vessel of the thrombosis due to adverse events exceeding 5 times previously reported

    In summary, this analysis analyzed 970.


    Amy natalizumab prevention method can effectively maintain a low rate of bleeding in patients of all ages PwHA or without the use of FVIII inhibitors, and well tolerated, not the emergence of new security risks Amy natalizumab prevention The method can effectively maintain a low bleeding rate in PwHA patients of all ages who use or do not use FVIII inhibitors, and is well tolerated, and there are no new safety hazards.


    Original source:

    Michael U.


    org/10.
    1182/blood.
    2020009217" target="_blank" rel="noopener">Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.